Diabetes at Sanofi is finished...

... and it's all happening right under your collective noses. You people are clueless.

http://www.biospace.com/News/eli-lilly-and-company-and-boehringer-ingelheim/319325

Glad I left.

 

And yet they still push the "SoloStar protects the Lantus exclusivity" lie.

 

Lillys gonna get cha.

 

Yes butt we will have the U-300 before you know it!

 

Funny about the Lilly situation. Most Sanofi employees don't know that the company is looking at a biosimilar for Lispro. A biosimilar Lispro probably has more upside that the faltering
rapid acting Sanofi is Pushing right now. And Lispro loses patent before glargine.
U-300 and Degludec will be the next generation basal insulins, Lilly pricing for biosimilar glargine won't win many managed care contracts. Biosimilar Glargine will have a worse launch than Detemir, and that's saying something.

 

Novo troll.

 

Yeah, ask the Lovenox reps how the biosimilar enoxaparin thing went for them. You are being lied to if you think even for a second this will work out ok.

And for the talking head poster trying to say that all there will be a generic biosimiar lispro, why will that have more upside? Won't it have to be accepted on managed care plans? But a generic biosimilar glargine will not? Your logic doesn't seem to be consistent.

 

Retired Lovenox/Lantus rep here. Anyone speculating when Lilly/BI will receive approval for their biosimilar?

 

Probs in Jan after the POTUS returns from Hawaii. The LLY CEO is a big backer and good friend.

 

U300 is baloney shit.

 

Is baloney shit, human shit after eating baloney or is it shit passed by a cheap, disgusting deli meat?

 

Certainly more upside than our current rapid, but not as much as bio sim glaring for Lilly.

 

Both would be better than U300.

 

I would still sleep with SL at 300.

 

A generic Lantus? Turn the lights out, party is over!

 

No such thing as generic insulin. Only biosimilars. No auto sub is allowed, meaning the Rx would have to be written for the glargine knock off. Would definitely affect formulary coverage if Lilly prices it cheaper, but they'll still need to promote it and get it written. Not a slam dunk, but would cause some challenges for Lantus, especially with all the price increases in the last couple of years.

 

Lilly is genius. They will beat us in ways we can't even imagine.

 

SS is pathetic pen.

 

Uhhh... speaking as a former Lovenox rep here... whether or not you call it "generic" or "biosimilar" I still lost my job selling Lovenox and became a six-figure base salary primary care Lantus rep because of the "biosimilar-generic" enoxaparin effect on the market.

The "generic" enoxaparin was substituted automatically in the retail market and the FDA gave it an equivalent rating. As soon as there was enough critical mass, most acute care accounts switched to generic enoxaparin.

Whatever the nomenclature, whatever spin you want to put on it, PEOPLE WILL LOSE THEIR JOBS HERE AT SANOFI. Period. End of story.

"...challenges for Lantus..." HA! Who do you think you are kidding here?

GET THOSE RESUMES READY FOLKS!

 

Great point and I agree. When would be your best guess as to the timing of the layoffs? August? December?